Teva, Pfizer settle on Viagra generic date

Share this article:

Teva announced yesterday afternoon that it had settled patent litigation with Pfizer and that the generics firm will be allowed to sell a copycat version of the blockbuster ED drug Viagra (sildenafil citrate) prior to the pill's official LOE date. Viagra's patent lapses in 2020, but this new settlement deal, terms of which the companies are keeping close to the vest, will allow the Israeli drug firm to roll out its copy by December 2017, Teva said, adding that it will pay a royalty to Pfizer for licensing. Its sildenafil ANDA has received tentative approval from the FDA. As of September 2013, Viagra had annual US sales of about $1.2 billion, according to IMS data cited by Teva.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Janssen recruits Debbie Allen for T2 Diabetes

Actress, choreographer and "So You Think You Can Dance" judge Debbie Allen has signed on to participate with the drugmaker's type 2 diabetes awareness and wellness program.

Pfizer seeks wider Xeljanz indication

The company expects to file an sNDA for plaque psoriasis next year.

Recalls dent Stryker Q1 earnings

Sales rose 5% compared to the same period last year.